Treating TNBS-induced colitis in rats with probiotics

Turkish Journal of Gastroenterology

Volumn 22, Issue 5, 2011, Pages 486-493

  Yue Meng, Wan ^a   You Qing, Zhu ^b   Bing, Xia ^b   Jun, Luo ^b  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Interleukin 10; Myeloperoxidase; Probiotic; Trinitrobenzene sulfonic acid; Tumor necrosis factor alpha; Ulcerative colitis

Indexed keywords

INTERLEUKIN 10; MYELOPEROXIDASE; OLSALAZINE; PEIFEIKANG; PROBIOTIC AGENT; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLON MUCOSA; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SPECTROPHOTOMETRY; THERAPY EFFECT;

AMINOSALICYLIC ACIDS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DRUG THERAPY, COMBINATION; FEMALE; INTERLEUKIN-10; PEROXIDASE; PROBIOTICS; RATS; RATS, SPRAGUE-DAWLEY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855446498     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: 10.4318/tjg.2011.0247     Document Type: Article

References (24)

1. Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997; 349: 521-4. (Pubitemid 27092789)
2. Targan SR, Hanuaer SB, van Deventer SJH, et al. A short term study of chimeric monoclonal antibody cA2 to tumour necrosis factor a for Crohn's disease. N Engl J Med 1997; 337: 1029-35.
3. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76. (Pubitemid 41770166)
4. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263-74. (Pubitemid 23320290)
5. Herfarth H, Bocker U, Janardhanam R, et al. Subtherapeutic corticosteroids potentiate the ability of interleukin-10 to prevent chronic inflammation in rats. Gastroenterology 1998; 115: 856-65. (Pubitemid 28452933)
6. Herfarth H, Mohanty S, Rath H, et al. Interleukin-10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers. Gut 1996; 39: 836-45. (Pubitemid 27049087)
7. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126: 1620-33. (Pubitemid 38649878)
8. Ghosh S, van Heel D, Playford RJ. Probiotics in inflammatory bowel disease: is it all gut flora modulation? Gut 2004; 53: 620-2. (Pubitemid 38561434)
9. Araki Y, Andoh A, Takizawa J, et al. Clostridium butyricum, a probiotic derivative, suppresses dextran sulfate sodium-induced experimental colitis in rats. Int J Mol Med 2004; 13: 577-80.
10. Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/SynergyI) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trail. Gut 2005; 54: 542-9.
11. Chen N, You P, Liu A, et al. The influence of T regulatory cells on experimental colitis of rats after treatment by probiotics. ZhongHuaXiaoHuaZaZhi 2006; 26: 100-3.
12. Siddiqui A, Ancha HR, Tedesco D, et al. Antioxidant therapy with N-acetylcysteine plus mesalamine accelerates mucosa healing in a rodent model of colitis. Dig Dis Sci 2006; 51: 698-705.
13. Vowinkel T, Kalogeris TJ, Mori M, et a1. Impact of dextran sulfate sodium load on the severity of inflammation in experimental colitis. Dig Dis Sci 2004; 49: 556-64.
14. Wallace JL, Keenan CM, Gale D, et al. Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis. Gastroenterology 1992; 102: 18-27.
15. Fedorak RN, Empey LR, MacArthur C, et al. Microstol provides a colonic mucosal protective effect during acetic acid induced colitis in rats. Gastroenterology 1990; 98: 615-25. (Pubitemid 20069696)
16. Morris GP, Beck PL, Herridge MS, et al. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989; 96: 795-803. (Pubitemid 19057602)
17. Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991; 32: 913-7.
18. Murch SH, Braegger CP, Walker-Smith JA, et al. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993; 34: 1705-9. (Pubitemid 23353163)
19. Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 89-91.
20. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000; 51: 289-98. (Pubitemid 30216038)
21. Castro-Santos P, Suarez A, Lopez-Rivas L, et al. TNFalpha and IL-10 gene polymorphisms in inflammatory bowel disease. Association of -1082 AA low producer IL-10 genotype with steroid dependency. Am J Gastroenterol 2006; 101: 1039-47. (Pubitemid 43725318)
22. Lindsay JO, Sandison A, Cohen P, et al. IL-10 gene therapy is therapeutic for dextran sodium sulfate-induced murine colitis. Dig Dis Sci 2004; 49: 1327-34. (Pubitemid 39178107)
23. Li MC, He SH. IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol 2004; 10: 620-5.
24. Siegmund B, Eigler A, Moeller J, et al. Suppression of tumor necrosis factor-alpha production by interleukin-10 is enhanced by cAMP-elevating agents. Eur J Pharmacol 1997; 321: 231-9. (Pubitemid 27089556)